Zura Bio Launches Global Phase 2 TibuSHIELD Study To Evaluate Tibulizumab In Adults With Hidradenitis Suppurativa, Topline Results For Primary Efficacy Endpoint At Week 16, Along With Key Secondary And Exploratory Outcomes, Are Anticipated In Third Quarte